https://www.hcplive.com/view/fda-priority-review-granted-zasocitinib-moderate-severe-psoriasis
FDA Priority Review Granted to Zasocitinib for Moderate to Severe Psoriasis | HCPLive
Oct 11, 2026 - Phase 3 data show zasocitinib use led to clear or almost clear skin in around 70% of patients by Week 16, setting up an FDA decision in early 2027.
priority reviewfdagrantedzasocitinibmoderate
https://kommunikasjon.ntb.no/pressemelding/19086680/zasocitinib-delivered-superior-efficacy-versus-deucravacitinib-in-new-phase-3-head-to-head-results-reinforcing-potential-to-deliver-rapid-and-durable-skin-clearance-in-a-convenient-once-daily-pill?publisherId=90063&lang=en
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results,...
Takeda (TSE:4502/NYSE:TAK) announced new data from threePhase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279), an investigational, next-generation,...
zasocitinibdeliveredsuperiorefficacyversus
https://touchderma.com/inflammatory-and-autoimmune-diseases/conference-hub/once-daily-oral-zasocitinib-demonstrates-superior-skin-clearance-versus-deucravacitinib-in-plaque-psoriasis/
Once-daily oral zasocitinib demonstrates superior skin clearance versus deucravacitinib in plaque...
In this video, we speak with Dr Linda Stein Gold (Henry Ford Health, Detroit, MI, USA), Director of Dermatology Clinical Research at Henry Ford Health and
dailyoralzasocitinibdemonstratessuperior
https://pj.jiho.jp/article/256364
Takeda’s Zasocitinib Gets FDA Priority Review in Plaque Psoriasis | PHARMA JAPAN
Takeda Pharmaceutical said on September 14 that the US FDA has accepted its new drug application for…
priority reviewplaque psoriasiszasocitinibgetsfda
https://www.clinicaltrialsdaily.com/zasocitinib-tyk2-plaque-psoriasis/
Zasocitinib: JH2 Selectivity, Phase 3 Efficacy, and the Road to Best-in-Class TYK2 Status in Plaque...
Mar 31, 2026 - Phase 3 LATITUDE data positions zasocitinib well above apremilast, while the pending NCT06973291 head-to-head trial against deucravacitinib will ultimately...
the road tobest in classzasocitinibselectivityphase